Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PYCR1 | P32322 | 8/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254052 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1PYCR1SIGMAR1HRH3 | |
| SCHEMBL1241978 | 0.82 | KDM4E (0.70) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL1241075 | 0.82 | KDM4E (0.69) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL10187442 | 0.80 | PYCR1 (0.69) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL69821 | 0.80 | PYCR1 (0.69) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL15128047 | 0.80 | PYCR1 (0.67) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL1241957 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL31612505 | 0.78 | KDM4E (0.64) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL308505 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1PYCR1MAOBTAAR1 | |
| SCHEMBL308737 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1PYCR1MAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | KDM4E 1214/4885ALDH1A1 3789/4885PYCR1 1553/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | KDM4E 1214/4885ALDH1A1 3789/4885PYCR1 1553/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | KDM4E 1214/4885ALDH1A1 3789/4885PYCR1 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.